Find, compare & contact
Artenimol
API Manufacturers & Suppliers
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Producer
Produced in:
Established in: 2021
MOQ: -
Employees: 19
API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides
Small quantity APIs to commercial scale
GMP and USFDA certification based on quantity, order, assignment.
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Artenimol API 71939-50-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Artenimol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Artenimol
- Synonyms:
- beta-Dihydroartemisinin , Dihydroartemisinin
- Cas Number:
- 71939-50-9
- DrugBank number:
- DB11638
- Unique Ingredient Identifier:
- 6A9O50735X
General Description:
Artenimol, identified by CAS number 71939-50-9, is a notable compound with significant therapeutic applications. Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections . It was first authorized for market by the European Medicines Agency in October 2011 in combination with as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization .
Indications:
This drug is primarily indicated for: For the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg . Used in combination with . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Artenimol undergoes metabolic processing primarily in: The primary metabolite of Artenimol is the glucuronide conjugate, α-artenimol-β-glucuronide . It is largely metabolized by UGT1A9 with some contribution by UGT2B7 . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Artenimol are crucial for its therapeutic efficacy: The reported oral bioavailability of Artenimol was reported to be 45% in healthy adults . The observed Tmax was 1-2 h This is known to increase in malaria infected patients which could be attributed to reduced metabolism by the liver or the drug's collection in infected erythrocytes. Artenimol was obeserved to have flip-flop kinetics with an overall absorption half-life of 1.04 h. When administered with food the AUC for Artenimol increases by 144%. Cmax was observed to increase by 129% but was not found to be statistically significant. Food was observed to delay Tmax by 1 h. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Artenimol is an important consideration for its dosing schedule: Artenimol was reported to have a half life of elimination of approximately 1 h . This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Artenimol exhibits a strong affinity for binding with plasma proteins: Artenimol has been reported to be 44-93% bound to plasma proteins . The identity of these proteins has not been reported. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Artenimol from the body primarily occurs through: Artenimol is eliminated via metabolism to glucuronide conjugates . There is little data on elimination of Artenimol but elimination of unchanged artemisinin compounds in feces and urine has been reported to be negligible. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Artenimol is distributed throughout the body with a volume of distribution of: Artenimol was observed to have a mean apparent volume of distribution of 0.801 L/kg in adult patients and 0.705 L/kg in pediatric patients wit *P. falciparum* malaria . This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Artenimol is a critical factor in determining its safe and effective dosage: Artenimol was observed to have a mean apparent clearance of 1.340 L/h/kg in adult patients and 1.450 L/h/kg in pediatric patients with *P. falciparum* malaria . It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Artenimol exerts its therapeutic effects through: Artenimol is thought to form a reactive carbon radical intermediate which kills *P. falciparum* through alkylation of a wide array of proteins. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Artenimol functions by: Artemisinins, including Artenimol which is a major active metabolite of many artemisinins, are thought to act via a common mechanism . While the exact mechanism of action is not certain, theories exist as to how artemisinins produce their antimalarial effect. Artemisinins are believed to bind to haem within the *P. falciparum* parasite . The source of this haem varies with the life stage of the parasite. When the parasite is in the early ring stage artemisinins are believed to bind haem produced by the parasite's haem biosynthesis pathway. In later stages artemisinins likely bind to haem released by haemoglobin digestion. Once bound to haem, artemisinins are thought to undergo activation involving ferrous iron via reductive scission which splits the endoperoxide bridge to produce a reactive oxygen . This reactive oxygen is thought to undergo a subsequent intramolecular hydrogen abstraction to produce a reactive carbon radical . The carbon radical is believed to be the source of the drugs potent activity against *P. falciparum* by alkylating a wide array of protein targets . The nature and magnitude of the effect on specific protein function as a result of this alkylation is unknown. One target which has been the focus of research is the sarco/endoplasmic reticulum Ca2+ ATPase pump of *P. falciparum* . Artemisinins have been found to irreversably bind to and inhibit this protein at a binding site similar to that of Thapsigargin. The mechanism is likely the same as for other proteins, namely alkylation via the carbon radical intermediate. Artemisinins appear to preferentially collect in infected erythrocytes, concentrating the drug by several hundred-fold compared to uninfected cells . This may play a role in why little alkylation is seen in uninfected erythrocytes . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Artenimol is categorized under the following therapeutic classes: Anti-Infective Agents, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Artemisia, Artemisinin and derivatives, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Free Radicals, Peroxides, Sesquiterpenes, Terpenes, UGT1A9 Substrates, UGT2B7 substrates. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Artenimol include:
- Melting Point: 164-165
Artenimol is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Artenimol manufacturers | traders | suppliers
We have 1 companies offering Artenimol produced in 1 different countries.
Get in contact with the supplier of your choice:
- SETV Global from India, product country of origin India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.